We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




AI to Improve Diagnosis of Atrial Fibrillation

By HospiMedica International staff writers
Posted on 10 May 2024

Abnormal heart rhythms frequently arise from—and contribute to—structural abnormalities in the heart. More...

Atrial fibrillation is a specific type of abnormal rhythm that may not be consistently present, often eluding detection during routine medical evaluations. In atrial fibrillation, the synchronization between the heart's upper and lower chambers can intermittently fail, complicating its diagnosis for healthcare professionals. While some individuals experience no symptoms from atrial fibrillation, others may suffer from heart palpitations, fatigue, shortness of breath, dizziness, and other issues that disrupt their everyday activities. If not addressed, atrial fibrillation can lead to severe complications such as stroke and heart failure. Now, researchers have developed an artificial intelligence (AI) program that is capable of identifying atrial fibrillation by analyzing images from echocardiograms—a common diagnostic test that utilizes sound waves to produce images of the heart.

A research team at Cedars-Sinai (Los Angeles, CA, USA) hypothesized that an AI tool designed to interpret echocardiograms could assist medical professionals in recognizing early, subtle cardiac changes in patients with undetected arrhythmias. They trained this AI system using over 100,000 video echocardiograms from patients diagnosed with atrial fibrillation. The system was able to differentiate between echocardiograms depicting normal sinus rhythm and those illustrating irregular rhythms. Additionally, it successfully predicted which patients currently in sinus rhythm were at risk of developing or having a recurrence of atrial fibrillation within the next 90 days. This AI model's performance in assessing the images surpassed traditional methods that predict risk based solely on established risk factors.

“We were able to show that a deep learning algorithm we developed could be applied to echocardiograms to identify patients with a hidden abnormal heart rhythm disorder called atrial fibrillation,” said Neal Yuan, MD, a staff scientist with the Smidt Heart Institute and first and corresponding author of the study. “Atrial fibrillation can come and go, so it might not be present at a doctor’s appointment. This AI algorithm identifies patients who might have atrial fibrillation even when it is not present during their echocardiogram study.”

Related Links:
Cedars-Sinai


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.